Current Report Filing (8-k)
November 14 2022 - 12:06PM
Edgar (US Regulatory)
0001589150
false
--09-30
0001589150
2022-11-03
2022-11-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November
3, 2022
REGEN BIOPHARMA, INC.
(Exact name of small business
issuer as specified in its charter)
Nevada |
45-5192997 |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
Commission File No.
333-191725
4700 Spring Street, St
304, La Mesa, California 91942
(Address of Principal Executive
Offices)
(619) 722 5505
(Issuer’s telephone
number)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
|
None |
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
5.03 Amendments to Articles of Incorporation
On
November 3, 2022, Section 1 of the Certificate of Designation of the Series A Preferred Stock of Regen Biopharma, Inc. was amended to
be and read as follows:
“The
shares of this series of preferred stock will be designated as Series A Preferred Stock (the “Series A Preferred”) which
series shall consist of seven hundred and thirty nine million (739,000,000) shares having a par value of $.0001 per share.”
Item
8.01 Other Events.
On
November 9, 2022 Regen Biopharma, Inc. presented at the Emerging Growth Conference. Video of the presentation can be accessed by the
public at through the following hyperlink:
https://youtu.be/EJmZ5WNzb3s
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
REGEN BIOPHARMA, INC. |
|
|
Dated: November 14, 2022
|
By: /s/ David Koos |
Regen Biopharma (PK) (USOTC:RGBP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Regen Biopharma (PK) (USOTC:RGBP)
Historical Stock Chart
From Sep 2023 to Sep 2024